Evaxion

Evaxion

Biotechnology
Evaxion AS is a techBio company based on its AI platform, AI-Immunology. Evaxion’s proprietary and scalable AI prediction models harness the power of artificial intelligence to decode the human immune system and develop novel immunotherapies for cancer, bacterial diseases, and viral infections. Evaxion has developed a clinical-stage oncology pipeline of novel personalised vaccines and a preclinical infectious disease pipeline in bacterial and viral diseases with high unmet medical needs. The group is committed to transforming patients’ lives by providing innovative and targeted treatment options.

$27.3M

Market Cap • 9/18/2026

2008

(18 years)

Founded

2021

(5 years ago)

IPO

NASDAQ

Listing Exchange

Flag of Denmark

Denmark

Country

Valuation

P/B

2,9

P/S

3,6

P/EBITDA

P/OCF

P/FCF

P/E

BVPS

2,8

EPS

Market Cap

Market Cap

27,3M

EV

20,4M

EV/Revenue

2,7

EV/EBITDA

-2,5

EV/EBIT

-2,3

Payout

Dividend Per Share

0

Dividend Yield

0%

Buyback Yield

0%

Total Yield

0%

Payout

0%

Retained Earnings

-133,6M

Profitability

Gross Margin

100%

EBITDA Margin

EBIT Margin

Net Margin

D&A/EBITDA

0%

R&D/Revenue

137,3%

Capex/Revenue

0%

Capex/D&A

0%

Capex/OCF

0%

SBC/OCF

% PPE

15,1%

% Goodwill

0%

ROE

ROIC

Growth

CAGR EPS 5Y

-29%

Leverage

N.D./EBITDA

0,9

Debt/Equity

0%

Current Ratio

5,1

Quick Ratio

5,1

Interest Coverage

Premium

Unlock 100% of the data and have immediate access on more than 6.000 companies with updated information!
  • Unrestricted access
  • Unlimited data history
  • Analysis videos
  • Quarterly highlights
  • Customizable financials table
  • Ranking
  • Discussions

...and much more!

Get Premium